Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy

NCT03902197 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT03902197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03902197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 2
Overall status
Unknown status
Start date
April 22, 2019
Completion date
December 21, 2023
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia